RVX-297- a novel BD2 selective inhibitor of BET bromodomains-Reference-Cited by-同舟云学术

RVX-297- a novel BD2 selective inhibitor of BET bromodomains

Published:2016-08 Issue:1 Volume:477 Page:62-67
ISSN:0006-291X
Container-title:Biochemical and Biophysical Research Communications
language:en
Short-container-title:Biochemical and Biophysical Research Communications

Author:

Kharenko Olesya A.^ORCID,Gesner Emily M.,Patel Reena G.,Norek Karen,White Andre,Fontano Eric,Suto Robert K.,Young Peter R.,McLure Kevin G.,Hansen Henrik C.

Publisher

Elsevier BV

Subject

Cell Biology,Molecular Biology,Biochemistry,Biophysics

Reference15 articles.

1. Targeting bromodomains: epigenetic readers of lysine acetylation;Filippakopoulos;Nat. Rev. Drug Discov.,2014

2. Inhibition of BET bromodomains as a therapeutic strategy for cancer drug discovery;Fu;Oncotarget,2015

3. RVX-208: a small molecule that increases apolipoprotein A-I and high-density lipoprotein cholesterol in vitro and in vivo;Bailey;J. Am. Coll. Cardiol.,2010

4. A novel BET bromodomain inhibitor, RVX-208, shows reduction of atherosclerosis in hyperlipidemic ApoE deficient mice;Jahagirdar;Atherosclerosis,2014

5. RVX-208, an inducer of ApoA-I in humans, is a BET bromodomain antagonist;McLure;PloS One,2013

Cited by 46 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. ABBV-744 alleviates LPS-induced neuroinflammation via regulation of BATF2-IRF4-STAT1/3/5 axis;Acta Pharmacologica Sinica;2024-06-11

2. Apabetalone (RVX-208): A Potential Epigenetic Therapy for the Treatment of Cardiovascular, Renal, Neurological, Viral, and Cancer Disorders;ACS Pharmacology & Translational Science;2024-02-06

3. DW71177: A novel [1,2,4]triazolo[4,3-a]quinoxaline-based potent and BD1-Selective BET inhibitor for the treatment of acute myeloid leukemia;European Journal of Medicinal Chemistry;2024-02

4. Bromodomain and extraterminal (BET) proteins: biological functions, diseases, and targeted therapy;Signal Transduction and Targeted Therapy;2023-11-06

5. Discovery of a Bromodomain and Extra Terminal Domain (BET) Inhibitor with the Selectivity for the Second Bromodomain (BD2) and the Capacity for the Treatment of Inflammatory Diseases;Journal of Medicinal Chemistry;2023-07-21